Developer docs
API playgroundTry for free, no card

Search company profiles

AION Labs

Full company profile

uuid00081so

Namestring
AION Labs
Legal namestring
AION Labs
Websiteurl
aionlabs.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

AION Labs is an Israel-based venture studio founded in 2021 in Rehovot that creates and funds AI-driven biotech startups targeting pharmaceutical R&D. The studio is structured as a unique partnership uniting four competing global pharmaceutical companies (AstraZeneca, Merck KGaA, Pfizer, Teva), technology partner AWS, and venture capital firms (Israel Biotech Fund, Amiti Ventures). Through a co-development model, AION Labs identifies pharma-defined unmet needs via open innovation challenges, recruits founders, and provides pre-seed funding of at least $500,000 per year for up to four years plus $100,000 in AWS cloud credits per startup, along with mentorship and operational support.

The studio's portfolio spans nine companies across diverse therapeutic and platform modalities, including antibody design (CombinAble, DenovAI), molecular glues (TenAces), RNA targeting (Renasis Bio), gene editing (Cassidy Bio), cancer therapeutics (Cellyrix), epiproteomics (Promise Bio), small molecule discovery (ProPhet), and pre-clinical safety analysis (Omec). AION Labs does not sell commercial products or services; its economics are built on equity stakes in portfolio companies, with returns realized through follow-on funding rounds and exits — exemplified by the January 2026 acquisition of CombinAble by Insitro, which also established Insitro's first R&D center in Israel.

The core technology proposition rests on a federated data platform that enables pre-competitive collaboration among rival pharma companies while maintaining data isolation, supported by AWS cloud infrastructure and hands-on R&D mentorship. Portfolio companies apply generative AI (diffusion models, LLMs), ML optimization, predictive analytics, and agentic architectures to drug discovery challenges. Portfolio funding milestones include Promise Bio's $8.3M seed and Cassidy Bio's $8M seed round, signaling market validation of the studio's company-building approach.

Short descriptiontext

AION Labs is an Israel-based venture studio, founded in 2021, that builds and funds AI-driven biotech startups in partnership with AstraZeneca, Merck, Pfizer, Teva, and AWS, providing pre-seed capital, pharma mentorship, and cloud infrastructure to portfolio companies focused on drug discovery and development.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRehovot, Israel
HQ citystring
Rehovot
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, venture studio services, pharma R&D, biotech startup incubation, AI platform development
Industry4 codes
PRIMARYFSANAHAC
Corporate Venture Studios & Incubators (Build/launch ventures)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHDAAACAA
Foundation Model Developers (LLM/Multimodal Model Labs)
Hardware, Technology & Telecom/Artificial Intelligence & Machine Learning/Foundation Models & Generative AI (LLMs, multimodal)
SECONDARYBPAEAHAF
AI/ML Engineering & Model Development Services
NAICS code4 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Scientific Research and Development Services5417
  • Management Consulting Services54161
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Prepackaged Software7372
  • Services-Management Consulting Services8742
Product category
Pharmaceutical AI Venture Studio / Biotech Incubation
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Equity stakes in portfolio companies
TypeLicensing Royalties
Description

AION Labs generates returns through equity ownership in the startups it creates and funds. As a venture studio, it takes equity in newly formed companies in exchange for pre-seed funding, pharma mentorship, operational support, and cloud credits. Returns are realized through follow-on funding rounds, M&A exits (e.g., CombinAble.AI acquired by Insitro), and potential IPOs.

aionlabs.com
2Strategic partnership fees
TypeManaged Services
Description

Pharma partners (AstraZeneca, Merck, Pfizer, Teva) and technology partners (AWS) provide funding, in-kind resources (cloud credits, mentorship time), and access to data/infrastructure in exchange for early access to innovations and co-ownership in the venture studio model.

aionlabs.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components2 values
Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

AION Labs is a venture studio that identifies unmet pharmaceutical R&D needs defined by partner pharma companies (AstraZeneca, Merck, Pfizer, Teva), recruits entrepreneurial founders through open innovation challenges, and builds AI-driven biotech startups by providing pre-seed funding ($500K+/year for up to 4 years), AWS cloud infrastructure and credits ($100K), pharma mentorship, and end-to-end operational support from ideation through growth. The studio takes equity stakes in the resulting companies and captures returns via follow-on funding rounds, M&A exits, and potential IPOs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 9 companies launched in over three years with multiple pharma pilots and collaborations
+3 more records
Product overview1 text field

AION Labs operates as a venture studio that builds and grows AI-powered biotech companies through a co-development model. The company unites competing pharmaceutical companies (AstraZeneca, Merck, Pfizer, Teva) with technology partners (AWS, Israel Biotech Fund, Amiti Ventures) to address pharma-defined unmet needs. The portfolio includes multiple portfolio companies at various stages: DenovAI and Promise Bio are active companies developing AI platforms for protein design and epiproteomics; TenAces and CombinAble focus on molecular glue and antibody optimization; Renasis Bio, Cassidy Bio, Cellyrix, and ProPhet represent newer ventures in RNA targeting, gene editing, cancer therapeutics, and small molecule discovery respectively; Omec addresses clinical trial prediction; CombinAble was acquired by Insitro. The model provides startups with early access to pharma insights, R&D validation, mentorship, and funding.

Product and service2 records
1AION Labs Venture Studio Program
CategoryVenture Studio Services
2CombinAble (CombinAble.AI)
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Insitro, a US-based AI-drug discovery unicorn, acquired CombinAble.AI (an AION Labs portfolio company), establishing their first R&D center in Israel based on the CombinAble team. This represents the first Israeli exit for an AI pharma startup.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-01
Description

Promise Bio emerged from stealth with $8.3M seed investment led by Awz Ventures, with participation from AstraZeneca and Pfizer via AION Labs. Promise Bio develops a computational epiproteomics and AI platform for precision medicine in immune-mediated diseases.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-10-01
Description

AstraZeneca is a founding pharma partner of AION Labs, providing R&D expertise, mentorship for portfolio companies, validation of unmet needs, and early adoption of AI-driven drug discovery solutions. AstraZeneca participates on the Board of Directors and Investment Committee.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-10-01
Description

Merck KGaA (known as EMD Serono in North America) is a founding pharma partner contributing R&D expertise, mentorship, and validation capabilities for AI-driven pharma startups created through the AION Labs venture studio.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-10-01
Description

Pfizer is a founding pharma partner providing R&D validation, mentorship from its global teams, and early commercial engagement opportunities for startups developing AI solutions for drug discovery and development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-10-01
Description

Teva Pharmaceuticals is a founding pharma partner and the Israeli anchor pharma company in AION Labs. Teva has led specific challenge calls, including the Entrepreneur in Residence program for AI-driven clinical trial control arms, and contributes R&D and operational expertise.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-10-01
Description

AWS provides cloud infrastructure, $100,000 in cloud credits per startup, and technology mentorship to help portfolio companies design platform architectures. AWS joined the pharma consortium and IBF in launching the AI therapeutics lab.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Biotech accelerator providing seed funding, mentorship, and lab infrastructure to science-driven startups. While IndieBio is broader (synthetic biology, food tech, etc.), its venture-building model for early-stage biotech is directly comparable to AION Labs' studio approach.

TypeBroad incumbent
Description

The largest and most established biotech venture studio, having created dozens of companies including Moderna. Operates a similar 'venture creation' model but at vastly greater scale and capital base. AION Labs is a smaller, regionally-focused analogue operating in the AI-pharma niche.

TypeBroad incumbent
Description

US-based AI-drug discovery unicorn and acquirer of AION Labs portfolio company CombinAble.AI. Insitro operates as a vertically integrated AI pharma company rather than a venture studio, but it represents a potential exit path and strategic partner for AION Labs portfolio companies.

4Israel Biotech Fund
TypeRegional player
Description

Founding VC partner of AION Labs and a regional biotech-focused venture capital firm. While IBF is a financial partner rather than a peer in the strictest sense, it operates in the same Israel biotech ecosystem and provides comparable venture-building expertise and follow-on capital.

TypeEmerging player
Description

AI-driven therapeutics company applying single-cell genomics and machine learning to drug discovery, with direct overlap to AION Labs portfolio company Cellyrix. Comparable in scale and stage as an emerging AI-pharma venture.

TypeBroad incumbent
Description

Public AI-driven drug discovery company combining high-throughput biology with machine learning. Operates a single integrated platform rather than a multi-venture studio model, but addresses the same pharma R&D transformation problem and competes for similar AI-pharma talent and partnerships.

TypeDirect peer
Description

Biotech startup accelerator historically focused on launching early-stage life science and pharma ventures from research institutions. Direct peer in the venture-builder-for-biotech category, though smaller in pharma-specific AI focus compared to AION Labs.

TypeEmerging player
Description

AI drug discovery company using structure-based deep learning for small molecule design. Direct overlap with AION Labs portfolio companies like ProPhet and TenAces, and similar pharma partnership model with companies including Sanofi and Eli Lilly.

TypeEmerging player
Description

AI-native drug discovery company founded in 2023 with significant capital from ARCH Venture Partners. Competes for the same AI-pharma talent and pharma partnerships that AION Labs' venture studio model is built around, though Xaira operates as a single company rather than a studio.

TypeDirect peer
Description

Independent biomedical research venture builder operating a challenge-based recruitment model similar to AION Labs, partnering with global pharma (Boehringer Ingelheim, Janssen, etc.) to launch biotech ventures. Both operate crowd-sourced idea competitions and co-development pipelines bridging pharma R&D with academic talent.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries9 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AION Labs

Pharmaceutical AI Venture Studio / Biotech Incubationaionlabs.com

AION Labs is an Israel-based venture studio, founded in 2021, that builds and funds AI-driven biotech startups in partnership with AstraZeneca, Merck, Pfizer, Teva, and AWS, providing pre-seed capital, pharma mentorship, and cloud infrastructure to portfolio companies focused on drug discovery and development.

What AION Labs does

AION Labs is an Israel-based venture studio founded in 2021 in Rehovot that creates and funds AI-driven biotech startups targeting pharmaceutical R&D. The studio is structured as a unique partnership uniting four competing global pharmaceutical companies (AstraZeneca, Merck KGaA, Pfizer, Teva), technology partner AWS, and venture capital firms (Israel Biotech Fund, Amiti Ventures). Through a co-development model, AION Labs identifies pharma-defined unmet needs via open innovation challenges, recruits founders, and provides pre-seed funding of at least $500,000 per year for up to four years plus $100,000 in AWS cloud credits per startup, along with mentorship and operational support.

The studio's portfolio spans nine companies across diverse therapeutic and platform modalities, including antibody design (CombinAble, DenovAI), molecular glues (TenAces), RNA targeting (Renasis Bio), gene editing (Cassidy Bio), cancer therapeutics (Cellyrix), epiproteomics (Promise Bio), small molecule discovery (ProPhet), and pre-clinical safety analysis (Omec). AION Labs does not sell commercial products or services; its economics are built on equity stakes in portfolio companies, with returns realized through follow-on funding rounds and exits — exemplified by the January 2026 acquisition of CombinAble by Insitro, which also established Insitro's first R&D center in Israel.

The core technology proposition rests on a federated data platform that enables pre-competitive collaboration among rival pharma companies while maintaining data isolation, supported by AWS cloud infrastructure and hands-on R&D mentorship. Portfolio companies apply generative AI (diffusion models, LLMs), ML optimization, predictive analytics, and agentic architectures to drug discovery challenges. Portfolio funding milestones include Promise Bio's $8.3M seed and Cassidy Bio's $8M seed round, signaling market validation of the studio's company-building approach.

AION Labs firmographics

Firmographics
Name
AION Labs
Legal name
AION Labs
Website
https://aionlabs.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
AION Labs is an Israel-based venture studio, founded in 2021, that builds and funds AI-driven biotech startups in partnership with AstraZeneca, Merck, Pfizer, Teva, and AWS, providing pre-seed capital, pharma mentorship, and cloud infrastructure to portfolio companies focused on drug discovery and development.
Ownership category
akta.pro rank

AION Labs industry classification

Industry
Product category
Pharmaceutical AI Venture Studio / Biotech Incubation
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417), Management Consulting Services (54161)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372), Services-Management Consulting Services (8742)
akta.pro industry
PRIMARYFSANAHAC
Corporate Venture Studios & Incubators (Build/launch ventures)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHDAAACAA
Foundation Model Developers (LLM/Multimodal Model Labs)
Hardware, Technology & Telecom/Artificial Intelligence & Machine Learning/Foundation Models & Generative AI (LLMs, multimodal)
SECONDARYBPAEAHAF
AI/ML Engineering & Model Development Services

Keywords

  • AI drug discovery
  • Venture studio services
  • Pharma R&D
  • Biotech startup incubation
  • AI platform development

Where AION Labs is headquartered

Location

Headquarters

HQ city
Rehovot
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

AION Labs business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations

Revenue model

  1. Equity stakes in portfolio companies: AION Labs generates returns through equity ownership in the startups it creates and funds. As a venture studio, it takes equity in newly formed companies in exchange for pre-seed funding, pharma mentorship, operational support, and cloud credits. Returns are realized through follow-on funding rounds, M&A exits (e.g., CombinAble.AI acquired by Insitro), and potential IPOs.
  2. Strategic partnership fees: Pharma partners (AstraZeneca, Merck, Pfizer, Teva) and technology partners (AWS) provide funding, in-kind resources (cloud credits, mentorship time), and access to data/infrastructure in exchange for early access to innovations and co-ownership in the venture studio model.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

AION Labs product offering

Product offering

Core offering

AION Labs is a venture studio that identifies unmet pharmaceutical R&D needs defined by partner pharma companies (AstraZeneca, Merck, Pfizer, Teva), recruits entrepreneurial founders through open innovation challenges, and builds AI-driven biotech startups by providing pre-seed funding ($500K+/year for up to 4 years), AWS cloud infrastructure and credits ($100K), pharma mentorship, and end-to-end operational support from ideation through growth. The studio takes equity stakes in the resulting companies and captures returns via follow-on funding rounds, M&A exits, and potential IPOs.

Product overview

AION Labs operates as a venture studio that builds and grows AI-powered biotech companies through a co-development model. The company unites competing pharmaceutical companies (AstraZeneca, Merck, Pfizer, Teva) with technology partners (AWS, Israel Biotech Fund, Amiti Ventures) to address pharma-defined unmet needs. The portfolio includes multiple portfolio companies at various stages: DenovAI and Promise Bio are active companies developing AI platforms for protein design and epiproteomics; TenAces and CombinAble focus on molecular glue and antibody optimization; Renasis Bio, Cassidy Bio, Cellyrix, and ProPhet represent newer ventures in RNA targeting, gene editing, cancer therapeutics, and small molecule discovery respectively; Omec addresses clinical trial prediction; CombinAble was acquired by Insitro. The model provides startups with early access to pharma insights, R&D validation, mentorship, and funding.

Differentiator

Problem solved

Functional benefit

Products and services

  • AION Labs Venture Studio Program
  • CombinAble (CombinAble.AI)

Quantifiable outcome

  • 9 companies launched in over three years with multiple pharma pilots and collaborations
  • +3 more outcomes

Companies that use AION Labs

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

AION Labs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature2 records

AION Labs partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core.

  • Insitro (acquirer of CombinAble.AI)coreStrategic or Co-development Partner · 1 January 2026Insitro, a US-based AI-drug discovery unicorn, acquired CombinAble.AI (an AION Labs portfolio company), establishing their first R&D center in Israel based on the CombinAble team. This represents the first Israeli exit for an AI pharma startup.
  • Promise Bio (Portfolio Company)coreStrategic or Co-development Partner · 1 December 2024Promise Bio emerged from stealth with $8.3M seed investment led by Awz Ventures, with participation from AstraZeneca and Pfizer via AION Labs. Promise Bio develops a computational epiproteomics and AI platform for precision medicine in immune-mediated diseases.
  • AstraZenecacoreStrategic or Co-development Partner · 1 October 2021AstraZeneca is a founding pharma partner of AION Labs, providing R&D expertise, mentorship for portfolio companies, validation of unmet needs, and early adoption of AI-driven drug discovery solutions. AstraZeneca participates on the Board of Directors and Investment Committee.
  • Merck KGaAcoreStrategic or Co-development Partner · 1 October 2021Merck KGaA (known as EMD Serono in North America) is a founding pharma partner contributing R&D expertise, mentorship, and validation capabilities for AI-driven pharma startups created through the AION Labs venture studio.
  • PfizercoreStrategic or Co-development Partner · 1 October 2021Pfizer is a founding pharma partner providing R&D validation, mentorship from its global teams, and early commercial engagement opportunities for startups developing AI solutions for drug discovery and development.
  • Teva PharmaceuticalscoreStrategic or Co-development Partner · 1 October 2021Teva Pharmaceuticals is a founding pharma partner and the Israeli anchor pharma company in AION Labs. Teva has led specific challenge calls, including the Entrepreneur in Residence program for AI-driven clinical trial control arms, and contributes R&D and operational expertise.
  • AWS (Amazon Web Services)coreTechnology or Integration · 1 October 2021AWS provides cloud infrastructure, $100,000 in cloud credits per startup, and technology mentorship to help portfolio companies design platform architectures. AWS joined the pharma consortium and IBF in launching the AI therapeutics lab.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

AION Labs competitors and assessment

Company assessment

Direct peers

  • IndieBio: Biotech accelerator providing seed funding, mentorship, and lab infrastructure to science-driven startups. While IndieBio is broader (synthetic biology, food tech, etc.), its venture-building model for early-stage biotech is directly comparable to AION Labs' studio approach.
  • Petri (SRI International): Biotech startup accelerator historically focused on launching early-stage life science and pharma ventures from research institutions. Direct peer in the venture-builder-for-biotech category, though smaller in pharma-specific AI focus compared to AION Labs.
  • BioMed X: Independent biomedical research venture builder operating a challenge-based recruitment model similar to AION Labs, partnering with global pharma (Boehringer Ingelheim, Janssen, etc.) to launch biotech ventures. Both operate crowd-sourced idea competitions and co-development pipelines bridging pharma R&D with academic talent.

Broad incumbents

  • Flagship Pioneering: The largest and most established biotech venture studio, having created dozens of companies including Moderna. Operates a similar 'venture creation' model but at vastly greater scale and capital base. AION Labs is a smaller, regionally-focused analogue operating in the AI-pharma niche.
  • Insitro: US-based AI-drug discovery unicorn and acquirer of AION Labs portfolio company CombinAble.AI. Insitro operates as a vertically integrated AI pharma company rather than a venture studio, but it represents a potential exit path and strategic partner for AION Labs portfolio companies.
  • Recursion Pharmaceuticals: Public AI-driven drug discovery company combining high-throughput biology with machine learning. Operates a single integrated platform rather than a multi-venture studio model, but addresses the same pharma R&D transformation problem and competes for similar AI-pharma talent and partnerships.

Regional players

  • Israel Biotech Fund: Founding VC partner of AION Labs and a regional biotech-focused venture capital firm. While IBF is a financial partner rather than a peer in the strictest sense, it operates in the same Israel biotech ecosystem and provides comparable venture-building expertise and follow-on capital.

Emerging players

  • Celsius Therapeutics: AI-driven therapeutics company applying single-cell genomics and machine learning to drug discovery, with direct overlap to AION Labs portfolio company Cellyrix. Comparable in scale and stage as an emerging AI-pharma venture.
  • Atomwise: AI drug discovery company using structure-based deep learning for small molecule design. Direct overlap with AION Labs portfolio companies like ProPhet and TenAces, and similar pharma partnership model with companies including Sanofi and Eli Lilly.
  • Xaira Therapeutics: AI-native drug discovery company founded in 2023 with significant capital from ARCH Venture Partners. Competes for the same AI-pharma talent and pharma partnerships that AION Labs' venture studio model is built around, though Xaira operates as a single company rather than a studio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

AION Labs social profiles

Digital presence

AION Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AION Labs leadership team

Management profile

Number of profiles

Profiles7 records

AION Labs subsidiaries and ownership

Company hierarchy

Subsidiaries9 records

AION Labs funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AION Labs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AION Labs

What does AION Labs do?

AION Labs is a venture studio that identifies unmet pharmaceutical R&D needs defined by partner pharma companies (AstraZeneca, Merck, Pfizer, Teva), recruits entrepreneurial founders through open innovation challenges, and builds AI-driven biotech startups by providing pre-seed funding ($500K+/year for up to 4 years), AWS cloud infrastructure and credits ($100K), pharma mentorship, and end-to-end operational support from ideation through growth. The studio takes equity stakes in the resulting companies and captures returns via follow-on funding rounds, M&A exits, and potential IPOs.

Is AION Labs a public or private company?

AION Labs is a private company. It is classified as venture growth investor backed and is currently operating.

When was AION Labs founded?

AION Labs was founded in 2021. It employs 11 to 50 people.

Where is AION Labs based?

AION Labs is headquartered in Rehovot, Israel, in the Middle East region.

How does AION Labs make money?

Two revenue lines are on record. Equity stakes in portfolio companies are the primary driver. The others are strategic partnership fees.

Who are AION Labs's main competitors?

Direct peers on record are IndieBio, Petri (SRI International) and BioMed X. Broad incumbents are Flagship Pioneering, Insitro and Recursion Pharmaceuticals. Israel Biotech Fund is listed as a regional player. Emerging players are Celsius Therapeutics, Atomwise and Xaira Therapeutics.

Does AION Labs have an API?

No public API is recorded for AION Labs.

What industry is AION Labs in?

AION Labs's product category is Pharmaceutical AI Venture Studio / Biotech Incubation. Its primary akta.pro industry code is FSANAHAC, Corporate Venture Studios & Incubators (Build/launch ventures), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooAION Labs Appoints New Scientific and Technology Leadership as It Expands Its Pharma R&D Innovation PlatformAION Labs appointed Dr. Ilana Mandel as Chief Scientific Officer and Dr. Shira Warszawski as Chief Technology Officer to support expansion across AI, biology, quantum, and other emerging technologies. The studio, founded by AstraZeneca, Merck, Pfizer, Teva, AWS, and others, has built 12 startups and completed over 22 proof-of-concept projects. Co-founder Yair Benita will step down to lead Phindex, a new venture.PR NewswireAION Labs Appoints New Scientific and Technology Leadership as It Expands Its Pharma R&D Innovation PlatformAION Labs appointed Dr. Ilana Mandel as Chief Scientific Officer and Dr. Shira Warszawski as Chief Technology Officer to support expansion into quantum, robotics, and automation. The studio, founded by major pharma and tech partners, has built 12 startups and completed over 22 proof-of-concept projects. Co-founder Yair Benita will step down to lead Phindex, an AI platform for drug development.Fnnews"AI Drug Development That Dramatically Reduces Cost and Time Is Near"... 160 Clinical Trials UnderwayAI drug development is rapidly advancing, with 160 candidates currently in clinical trials, driven by startups supported by AION Labs and collaborations with major pharmaceutical companies. Notably, AI has significantly shortened drug discovery times and reduced costs, exemplified by Insilico Medicine's discovery of a fibrosis treatment in 46 days.AionlabsThe future of pharmaAION Labs, a venture studio founded by global pharma and technology leaders, is launching initiatives to build AI companies focused on drug discovery. The studio utilizes two tracks, AION Building and AION Seeding, to fund and support early-stage startups and scientists in developing transformative health technologies.ForbesIsraeli Startups Using AI To Accelerate Drug DiscoveryAION Labs, an Israeli venture studio, is building AI startups to accelerate drug discovery, partnering with Pfizer, AstraZeneca, Teva, and Merck. It cites $145 billion in pharma R&D spending and predicts AI-designed drugs could reach approval by 2030. The studio also supports startups like DenovAI and Cassidy Bio.CEOWORLD magazineAI-First Business Models Seek to Reshape Drug DiscoveryAION Labs, an Israel-based venture studio, is launching its first 2025 Global Call for Applications for a generative AI startup focused on multi-target drug discovery. The company's AI-first model creates startups from scratch with direct access to pharmaceutical partners like AstraZeneca and Pfizer. Its ventures, including Promise Bio, aim to reduce drug development costs and improve patient outcomes.PR NewswireAION Labs, In Continued Partnership with BioMed X, Launches 2025 Global Call for Applications: Generative AI for Novel Target CombinationsAION Labs and BioMed X launched a global call for applications to form a new startup focused on generative AI for novel target combinations. The startup will develop an AI-driven platform to identify and validate molecular target combinations for multispecific biologic drugs, with applications due May 5, 2025.PR NewswirePromise Bio Emerges from Stealth with $8.3M Seed Investment to Transform Precision Medicine for Immune-Mediated DiseasesPromise Bio emerged from stealth with an $8.3 million seed investment led by Awz Ventures, with funding from AstraZeneca and Pfizer via AION Labs. The company's platform uses epiproteomics and AI to predict treatment responses for immune-mediated diseases, aiming to improve the 30-40% remission rate. The funding will accelerate platform development and build a large PTM database.Business & FinancialAION Labs Launches New AI Startup To Accelerate Identification Of Active Small Molecules For Drug DiscoveryAION Labs launched ProPhet, an AI startup to identify active small molecules for drug discovery. The company uses machine learning, including diffusion models and large language models, to screen small molecule libraries against target proteins. It aims to reduce time and cost in early drug discovery.PR NewswireAION Labs Launches New AI Startup to Accelerate Identification of Active Small Molecules for Drug DiscoveryAION Labs launched ProPhet, an AI startup to identify active small molecules for drug discovery. The company uses machine learning, including diffusion models and large language models, to screen small molecule libraries against target proteins. It aims to reduce time and cost in early drug discovery.